Lowdell Mark William 4

Accession 0001213900-25-112236

CIK 0001711754other

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 5:29 PM ET

Size

26.2 KB

Accession

0001213900-25-112236

Form 4

Period: 2025-11-18

Chief Scientific Officer

Transactions

Award
Stock Option (right to buy)
2025-11-18+180,000→ 180,000 total
Exercise: $1.50Exp: 2029-11-24→ Common Stock (180,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-11-18−104,000→ 0 total
Exercise: $7.92Exp: 2032-03-20→ Common Stock (104,000 underlying)
Award
Stock Option (right to buy)
2025-11-18+140,000→ 140,000 total
Exercise: $1.50Exp: 2034-12-04→ Common Stock (140,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-11-18−100,000→ 0 total
Exercise: $9.92Exp: 2034-05-13→ Common Stock (100,000 underlying)
Award
Stock Option (right to buy)
2025-11-18+104,000→ 104,000 total
Exercise: $1.50Exp: 2032-03-20→ Common Stock (104,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-11-18−180,000→ 0 total
Exercise: $3.91Exp: 2029-11-24→ Common Stock (180,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-11-18−400,000→ 0 total
Exercise: $7.80Exp: 2028-01-01→ Common Stock (400,000 underlying)
Award
Stock Option (right to buy)
2025-11-18+400,000→ 400,000 total
Exercise: $1.50Exp: 2028-01-01→ Common Stock (400,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2025-11-18−140,000→ 0 total
Exercise: $5.05Exp: 2034-12-04→ Common Stock (140,000 underlying)
Award
Stock Option (right to buy)
2025-11-18+100,000→ 100,000 total
Exercise: $1.50Exp: 2034-05-13→ Common Stock (100,000 underlying)

Footnotes (2)

[F1]Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
[F2]This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Documents

1 file

Inmune Bio, Inc.

CIK 0001711754

Entity typeother